Consolidated Balance Sheet - USD ($) $ in Millions		Sep. 30, 2024	Dec. 31, 2023
Assets
Cash and due from banks		$ 73,562	$ 61,192
Investment securities
Held-to-maturity (fair value $71,415 and $74,088, respectively)		80,025	84,045
Available-for-sale ($313 and $338 pledged as collateral, respectively)	[1]	81,704	69,706
Loans held for sale (including $2,887 and $2,011 of mortgage loans carried at fair value, respectively)		3,211	2,201
Loans
Total loans		374,164	373,835
Less allowance for loan losses		(7,560)	(7,379)
Net loans		366,604	366,456
Premises and equipment		3,585	3,623
Goodwill		12,573	12,489
Other intangible assets		5,488	6,084
Other assets (including $7,490 and $3,548 of trading securities at fair value pledged as collateral, respectively)	[1]	59,717	57,695
Total assets		686,469	663,491
Deposits
Noninterest-bearing		86,838	89,989
Interest-bearing (including $7,655 and $2,818 of time deposits carried at fair value, respectively)		434,293	422,323
Total deposits		521,131	512,312
Short-term borrowings		23,708	15,279
Long-term debt		54,839	51,480
Other liabilities		27,470	28,649
Total liabilities		627,148	607,720
Shareholders’ equity
Preferred stock		6,808	6,808
Common stock, $.01 par value per share, authorized: 4,000,000,000 shares; issued: 9/30/24 and 12/31/23—2,125,725,742 shares		21	21
Capital surplus		8,729	8,673
Retained earnings		76,057	74,026
Less cost of common stock in treasury: 9/30/24—565,004,098 shares; 12/31/23—567,732,687 shares		(24,010)	(24,126)
Accumulated other comprehensive income (loss)		(8,746)	(10,096)
Total U.S. Bancorp shareholders’ equity		58,859	55,306
Noncontrolling interests		462	465
Total equity		59,321	55,771
Total liabilities and equity		686,469	663,491
Commercial | Commercial
Loans
Total loans		133,638	131,881
Commercial | Commercial real estate
Loans
Total loans		50,619	53,455
Consumer | Residential mortgages
Loans
Total loans		118,034	115,530
Consumer | Credit card
Loans
Total loans		29,037	28,560
Consumer | Other retail
Loans
Total loans		$ 42,836	$ 44,409

[1] Includes only collateral pledged by the Company where counterparties have the right to sell or pledge the collateral.